Multiplex Assay Kit for Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay)

CXCL7; PPBP; PBP; B-TG1; CTAP-III; CTAP3; CTAPIII; LA-PF4; LDGF; MDGF; NAP2; SCYB7; TC1; TC2; TGB1; THBGB1; Pro-Platelet Basic Protein; Beta-Thromboglobulin

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 89-103 94
EDTA plasma(n=5) 78-99 87
heparin plasma(n=5) 97-105 102

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 87-102% 94-103% 83-97% 85-99%
EDTA plasma(n=5) 82-94% 83-91% 97-105% 88-96%
heparin plasma(n=5) 88-102% 89-98% 85-94% 80-96%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#: CXCL7) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Clinical Hemorheology and Microcirculation Strict heart rate control attenuates prothrombotic state and platelet activity in patients with non-valvular permanent atrial fibrillation. Pubmed: 2347822
International Journal of Pharma & Bio Sciences STUDIES ON THE STORAGE OF POOLED PLATELETS IN NON DOP PVC CONTAINERS Ebscohost: Source
Journal of Affective Disorders Bioprofiling of platelets in medicated patients with depression. Pubmed:25451399
Perfusion Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testing PubMed: 26243277
Physiol Behav Differential changes in platelet reactivity induced by acute physical compared to persistent mental stress PubMed: 26192713
J Affect Disord Bioprofiling of platelets in medicated patients with depression PubMed: 25451399
Turk Kardiyol Dern Ars Markers of coagulation and fibrinolysis do not detect or predict the presence of left atrial appendage thrombus in patients with atrial fibrillation Pubmed: 32147650
JOURNAL OF FOOD BIOCHEMISTRY A novel di‐peptide Met‐Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq‐mediated signaling Pubmed: 32662128
Membranes (Basel) Endogenous Nitric Oxide-Releasing Microgel Coating Prevents Clot Formation on Oxygenator Fibers Exposed to In Vitro Blood Flow Pubmed:35054599
Vaccine The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats Pubmed:35183388
Catalog No. Related products for research use of Oryctolagus cuniculus (Rabbit) Organism species Applications (RESEARCH USE ONLY!)
RPA370Rb01 Recombinant Chemokine (C-X-C motif) ligand 7 ( CXCL7) Positive Control; Immunogen; SDS-PAGE; WB.
PAA370Rb01 Polyclonal Antibody to Chemokine (C-X-C motif) ligand 7 ( CXCL7) WB; IHC; ICC; IP.
SEA370Rb ELISA Kit for Chemokine (C-X-C motif) ligand 7 ( CXCL7) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA370Rb Multiplex Assay Kit for Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.